Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Neoplasms | 4 | 2025 | 223 | 1.120 |
Why?
|
| Chemokine CCL20 | 2 | 2025 | 9 | 0.970 |
Why?
|
| Fluorouracil | 2 | 2025 | 46 | 0.960 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2025 | 26 | 0.940 |
Why?
|
| Interleukin-10 | 1 | 2025 | 86 | 0.900 |
Why?
|
| Receptors, CCR | 2 | 2021 | 24 | 0.790 |
Why?
|
| Neutrophils | 1 | 2022 | 141 | 0.710 |
Why?
|
| Immunotherapy | 1 | 2022 | 137 | 0.680 |
Why?
|
| Receptors, Virus | 2 | 2016 | 22 | 0.580 |
Why?
|
| Receptors, Chemokine | 2 | 2016 | 72 | 0.570 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 130 | 0.500 |
Why?
|
| Andrographis | 1 | 2016 | 4 | 0.490 |
Why?
|
| Receptors, CXCR | 1 | 2016 | 6 | 0.490 |
Why?
|
| Receptors, CXCR3 | 1 | 2016 | 31 | 0.490 |
Why?
|
| Cell Line, Tumor | 9 | 2025 | 2598 | 0.480 |
Why?
|
| Metalloproteases | 1 | 2015 | 17 | 0.460 |
Why?
|
| Diterpenes | 1 | 2016 | 94 | 0.460 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 406 | 0.440 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 134 | 0.430 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 933 | 0.420 |
Why?
|
| Epithelial Cells | 2 | 2018 | 426 | 0.410 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 479 | 0.390 |
Why?
|
| Cell Movement | 6 | 2019 | 640 | 0.370 |
Why?
|
| Signal Transduction | 5 | 2025 | 2111 | 0.310 |
Why?
|
| Apoptosis | 5 | 2019 | 1541 | 0.290 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 233 | 0.270 |
Why?
|
| Chemokines, CC | 2 | 2019 | 53 | 0.250 |
Why?
|
| Receptors, Scavenger | 2 | 2016 | 15 | 0.240 |
Why?
|
| Chemokines, CXC | 2 | 2016 | 36 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2025 | 290 | 0.220 |
Why?
|
| Prostatic Neoplasms | 3 | 2019 | 1068 | 0.210 |
Why?
|
| Humans | 14 | 2025 | 42163 | 0.200 |
Why?
|
| Immunologic Factors | 1 | 2022 | 50 | 0.190 |
Why?
|
| Chemokines | 2 | 2017 | 97 | 0.160 |
Why?
|
| Cell Proliferation | 4 | 2019 | 1420 | 0.160 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2019 | 35 | 0.150 |
Why?
|
| Cytoskeleton | 2 | 2018 | 111 | 0.150 |
Why?
|
| Cell Survival | 3 | 2018 | 934 | 0.150 |
Why?
|
| Matrix Metalloproteinases | 1 | 2019 | 49 | 0.150 |
Why?
|
| Proanthocyanidins | 1 | 2018 | 3 | 0.150 |
Why?
|
| Adherens Junctions | 1 | 2018 | 11 | 0.140 |
Why?
|
| Ovary | 1 | 2019 | 112 | 0.140 |
Why?
|
| Tight Junctions | 1 | 2018 | 27 | 0.140 |
Why?
|
| Quercetin | 1 | 2018 | 46 | 0.140 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 366 | 0.140 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2018 | 160 | 0.130 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2016 | 7 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 1679 | 0.130 |
Why?
|
| Phosphoproteins | 1 | 2018 | 201 | 0.130 |
Why?
|
| Phosphorylation | 2 | 2018 | 973 | 0.130 |
Why?
|
| Cytokines | 2 | 2017 | 661 | 0.130 |
Why?
|
| Receptors, CCR6 | 1 | 2016 | 3 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 209 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 1112 | 0.130 |
Why?
|
| Azoxymethane | 1 | 2016 | 7 | 0.120 |
Why?
|
| Dictyostelium | 1 | 2016 | 48 | 0.120 |
Why?
|
| Dextran Sulfate | 1 | 2016 | 17 | 0.120 |
Why?
|
| Chemokine CXCL11 | 1 | 2016 | 7 | 0.120 |
Why?
|
| Cyclin B1 | 1 | 2016 | 18 | 0.120 |
Why?
|
| CDC2 Protein Kinase | 1 | 2016 | 20 | 0.120 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 25 | 0.120 |
Why?
|
| Cyclins | 1 | 2016 | 37 | 0.120 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2016 | 17 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 32 | 0.120 |
Why?
|
| Retinoblastoma Protein | 1 | 2016 | 29 | 0.120 |
Why?
|
| Membrane Proteins | 2 | 2019 | 548 | 0.120 |
Why?
|
| Cell Growth Processes | 1 | 2015 | 43 | 0.120 |
Why?
|
| ADAM Proteins | 1 | 2015 | 20 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 2016 | 131 | 0.110 |
Why?
|
| Cytoskeletal Proteins | 1 | 2016 | 114 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 165 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 139 | 0.110 |
Why?
|
| Prostate | 1 | 2016 | 152 | 0.110 |
Why?
|
| Histones | 1 | 2016 | 194 | 0.110 |
Why?
|
| Ethanol | 1 | 2016 | 221 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 330 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 239 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 979 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2016 | 303 | 0.100 |
Why?
|
| Inflammation | 1 | 2016 | 729 | 0.080 |
Why?
|
| Disease Progression | 3 | 2019 | 661 | 0.080 |
Why?
|
| Drug Synergism | 2 | 2019 | 189 | 0.070 |
Why?
|
| Female | 4 | 2019 | 24018 | 0.060 |
Why?
|
| Protein Transport | 2 | 2016 | 295 | 0.060 |
Why?
|
| Male | 4 | 2019 | 22779 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2016 | 411 | 0.060 |
Why?
|
| Calcium | 2 | 2018 | 487 | 0.050 |
Why?
|
| Prognosis | 2 | 2018 | 850 | 0.050 |
Why?
|
| Models, Biological | 2 | 2017 | 711 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2019 | 1265 | 0.050 |
Why?
|
| Fluorescence Recovery After Photobleaching | 1 | 2018 | 9 | 0.040 |
Why?
|
| Intercellular Junctions | 1 | 2018 | 18 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2018 | 55 | 0.030 |
Why?
|
| Point Mutation | 1 | 2018 | 98 | 0.030 |
Why?
|
| Dogs | 1 | 2018 | 201 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2018 | 207 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 301 | 0.030 |
Why?
|
| RNA, Antisense | 1 | 2016 | 18 | 0.030 |
Why?
|
| Annexin A5 | 1 | 2016 | 27 | 0.030 |
Why?
|
| Propidium | 1 | 2016 | 20 | 0.030 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2016 | 25 | 0.030 |
Why?
|
| Fluorometry | 1 | 2016 | 17 | 0.030 |
Why?
|
| Cell Shape | 1 | 2016 | 42 | 0.030 |
Why?
|
| NAD | 1 | 2016 | 45 | 0.030 |
Why?
|
| Cytosol | 1 | 2016 | 98 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2016 | 89 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2016 | 106 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2019 | 355 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 111 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2016 | 205 | 0.030 |
Why?
|
| Cell Death | 1 | 2016 | 277 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 284 | 0.030 |
Why?
|
| Glucose | 1 | 2016 | 242 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2016 | 237 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 348 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 506 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 170 | 0.030 |
Why?
|
| Antioxidants | 1 | 2018 | 439 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 452 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 683 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 649 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2018 | 1586 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 928 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 884 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 518 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 692 | 0.020 |
Why?
|
| Mitochondria | 1 | 2016 | 516 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 287 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1266 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 990 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 16695 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 6490 | 0.010 |
Why?
|